215 related articles for article (PubMed ID: 11715834)
1. Fondaparinux sodium: a selective inhibitor of factor Xa.
Bauer KA
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S14-7. PubMed ID: 11715834
[TBL] [Abstract][Full Text] [Related]
2. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
Turpie AG
Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation.
Mahieu E; Claes K; Jacquemin M; Evenepoel P; Op De Beek K; Bogaert AM; Kuypers D; Verhamme P; Meijers B
Artif Organs; 2013 May; 37(5):482-7. PubMed ID: 23461610
[TBL] [Abstract][Full Text] [Related]
4. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa.
Petitou M; Duchaussoy P; Herbert JM; Duc G; El Hajji M; Branellec JF; Donat F; Necciari J; Cariou R; Bouthier J; Garrigou E
Semin Thromb Hemost; 2002 Aug; 28(4):393-402. PubMed ID: 12244487
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
[TBL] [Abstract][Full Text] [Related]
6. Fondaparinux sodium.
Reverter JC
Drugs Today (Barc); 2002 Mar; 38(3):185-94. PubMed ID: 12532174
[TBL] [Abstract][Full Text] [Related]
7. Setting a standard for venous thromboembolism prophylaxis.
Turpie AG
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S18-23. PubMed ID: 11715835
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
Walenga JM; Jeske WP; Samama MM; Frapaise FX; Bick RL; Fareed J
Expert Opin Investig Drugs; 2002 Mar; 11(3):397-407. PubMed ID: 11866668
[TBL] [Abstract][Full Text] [Related]
9. Fondaparinux monitoring in a patient with heparin-induced thrombocytopenia on hemodialysis.
Kušić J; Kulić A; Djurković V; Marković R; Milačić V; Surić-Lambić L; Peković G
Srp Arh Celok Lek; 2016; 144(11-12):654-6. PubMed ID: 29659233
[TBL] [Abstract][Full Text] [Related]
10. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
[TBL] [Abstract][Full Text] [Related]
11. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents - the selective factor Xa inhibitors.
Bauer KA; Hawkins DW; Peters PC; Petitou M; Herbert JM; van Boeckel CA; Meuleman DG
Cardiovasc Drug Rev; 2002; 20(1):37-52. PubMed ID: 12070533
[TBL] [Abstract][Full Text] [Related]
12. Use of the pentasaccharide fondaparinux as an anticoagulant during haemodialysis.
Kalicki RM; Aregger F; Alberio L; Lämmle B; Frey FJ; Uehlinger DE
Thromb Haemost; 2007 Dec; 98(6):1200-7. PubMed ID: 18064314
[TBL] [Abstract][Full Text] [Related]
13. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
14. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.
Lobo B; Finch C; Howard A; Minhas S
Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156
[TBL] [Abstract][Full Text] [Related]
15. Factor Xa inhibitors: new anti-thrombotic agents and their characteristics.
Ieko M; Tarumi T; Nakabayashi T; Yoshida M; Naito S; Koike T
Front Biosci; 2006 Jan; 11():232-48. PubMed ID: 16146728
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: Comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux.
Honda Y; Kamisato C; Morishima Y
Thromb Res; 2016 May; 141():17-21. PubMed ID: 26962981
[TBL] [Abstract][Full Text] [Related]
17. Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT)--bridging the River Coumarin.
Warkentin TE
Thromb Haemost; 2008 Jan; 99(1):2-3. PubMed ID: 18217128
[No Abstract] [Full Text] [Related]
18. Limitations of traditional anticoagulants.
Hawkins D
Pharmacotherapy; 2004 Jul; 24(7 Pt 2):62S-65S. PubMed ID: 15317400
[TBL] [Abstract][Full Text] [Related]
19. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology.
Bauer KA
Chest; 2003 Dec; 124(6 Suppl):364S-370S. PubMed ID: 14668419
[TBL] [Abstract][Full Text] [Related]
20. [Monitoring anticoagulation by fondaparinux: determination of anti factor Xa-level].
Dämgen-von Brevern G; Kläffling C; Lindhoff-Last E
Hamostaseologie; 2005 Aug; 25(3):281-5. PubMed ID: 16113752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
